文献速递前列腺增生与排尿功能障碍

锯叶棕+硒+番茄红素与他达拉非5mg治疗良性前列腺梗阻所致下尿路症状:SPRITE IV期非劣效开放标签临床研究

Serenoa repens + selenium + lycopene vs tadalafil 5 mg for the treatment of lower urinary tract symptoms secondary to benign prostatic obstruction: a Phase IV, non-inferiority, open-label, clinical study (SPRITE study).
PubMed 文献 · BJU Int · 2018-04-16

SPRITE研究为随机、开放标签、非劣效IV期临床试验,纳入427例50-80岁、IPSS≥12、Qmax≤15 mL/s、PVR<100 mL的LUTS患者,按2:1随机接受锯叶棕+硒+番茄红素(SeR-Se-Ly)或他达拉非5mg治疗6个月。主要终点为IPSS和Qmax的非劣效变化,结果显示SeR-Se-Ly组在IPSS中位变化、IPSS生活质量及Qmax中位变化上均非劣于他达拉非5mg组,且不良反应发生率更低。

要点

  • SeR-Se-Ly在改善IPSS和Qmax方面非劣于他达拉非5mg。
  • SeR-Se-Ly组Qmax增加≥3分及≥30%的患者比例显著高于他达拉非组。
  • SeR-Se-Ly组不良反应发生率(1.44%)显著低于他达拉非组(7.81%)。

核心结论

  • SeR-Se-Ly治疗在改善LUTS患者IPSS和Qmax方面非劣于他达拉非5mg。

研究设计与样本

  • 随机、开放标签、非劣效IV期临床研究,2015年5月至2017年1月纳入21个中心427例患者。
  • 纳入标准:年龄50-80岁,IPSS≥12,Qmax≤15 mL/s,PVR<100 mL。
  • 按2:1随机分为SeR-Se-Ly组(每日1片,6个月)和他达拉非5mg组(每日1片,6个月)。
  • 404例完成全方案。

主要发现

  • IPSS中位变化:SeR-Se-Ly组-3.0 vs 他达拉非组-3.0(P<0.01),非劣效。
  • IPSS生活质量中位变化:-2.0 vs -2.0(P<0.05),非劣效。
  • Qmax中位变化:2.0 vs 2.0 mL/s(P<0.01),非劣效。
  • Qmax增加≥3分的患者比例:38.2% vs 28.1%(P=0.04),SeR-Se-Ly组更高。
  • Qmax增加≥30%的患者比例:39.2% vs 27.3%(P<0.01),SeR-Se-Ly组更高。

关键数值与推荐

  • 非劣效主要终点:IPSS和Qmax中位变化,SeR-Se-Ly组均非劣于他达拉非5mg组(P<0.01)。
  • Qmax增加≥3分比例38.2% vs 28.1%(P=0.04);Qmax增加≥30%比例39.2% vs 27.3%(P<0.01)。
  • 不良反应发生率1.44% vs 7.81%(P<0.05)。

临床怎么用

  • 对于LUTS患者,SeR-Se-Ly可作为他达拉非5mg的非劣效替代选择,且不良反应更少。
  • SeR-Se-Ly在改善Qmax幅度上可能更具优势。

局限性

  • 开放标签设计可能引入偏倚。
  • 研究未设安慰剂对照。
  • 随访时间仅6个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare in a randomised, open-label, non-inferiority clinical study, the efficacy and tolerability of Serenoa repens (SeR) + selenium (Se) + lycopene (Ly) (SeR-Se-Ly) therapy vs tadalafil 5 mg in men with lower urinary tract symptoms (LUTS). PATIENTS AND METHODS: From May 2015 to January 2017, 427 patients were enrolled in 21 different centres (International Standard Randomised Controlled Trial Number Register [ISRCTN] 73316039). Inclusion criteria included: age between 50 and 80 years, International Prostate Symptom Score (IPSS) ≥12, maximum urinary flow rate (Qmax ) ≤ 15 mL/s, and post-void residual (PVR) <100 mL. Patients were randomised into two groups in a 2:1 ratio: Group A (SeR-Se-Ly, 1 tablet daily for 6 months) and Group B (tadalafil 5 mg, 1 tablet daily for 6 months). The primary endpoint of the study was the non-inferior variation in the IPSS and Qmax in Group A vs Group B after 6 months of treatment. RESULTS: In all, 404 patients completed the full protocol. When comparing both therapies, Group A was statistically not inferior to Group B considering the median change in IPSS (-3.0 vs -3.0; P < 0.01), IPSS quality of life (-2.0 vs -2.0; P < 0.05), and Qmax (2.0 vs 2.0 mL/s; P < 0.01). We found statistically significant differences in the increase of at least 3 points in Qmax (38.2% vs 28.1%; P = 0.04) and of at least 30% of Qmax (39.2% vs 27.3%; P < 0.01) in Group A compared to Group B. The percentage of patients with an increase of at least 3 points in the IPSS and a decrease of at least 25% of the IPSS was not statistically different between the two groups. For adverse events, four patients in Group A (1.44%) and 10 in Group B (7.81%) (P < 0.05) reported side-effects. CONCLUSION: We have shown that treatment with SeR-Se-Ly was not inferior to tadalafil 5 mg for improving IPSS and Qmax in men with LUTS.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Morgia G, Vespasiani G, Pareo RM, et al. Serenoa repens + selenium + lycopene vs tadalafil 5 mg for the treatment of lower urinary tract symptoms secondary to benign prostatic obstruction: a Phase IV, non-inferiority, open-label, clinical study (SPRITE study). BJU Int. 2018. PMID: 29569389. doi:10.1111/bju.14209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。